XML 23 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenues:        
Total revenues $ 38,469 $ 29,784 $ 87,132 $ 61,911
Cost of revenues:        
Total cost of revenues 21,335 17,804 42,015 33,767
Gross profit 17,134 11,980 45,117 28,144
Operating expenses:        
Research and development 31,123 21,092 58,945 42,540
Sales and marketing 7,428 5,380 14,099 10,619
General and administrative 22,056 15,850 44,189 29,239
Total operating expenses 60,607 42,322 117,233 82,398
Loss from operations (43,473) (30,342) (72,116) (54,254)
Other income (expense):        
Gain (loss) on equity investments 11,828   11,828 (1,781)
Change in fair value (15,700) (4,918) (21,864) 19,906
Other (expense) income (296) 357 32 777
Total other (expense) income (4,168) (4,561) (10,004) 18,902
Loss before income taxes (47,641) (34,903) (82,120) (35,352)
Income tax expense 33 67 5 141
Net loss (47,674) (34,970) (82,125) (35,493)
Net income (loss) attributable to noncontrolling interest 12 (326) 1 (820)
Net loss attributable to Schrödinger common and limited common stockholders $ (47,686) $ (34,644) $ (82,126) $ (34,673)
Net loss per share attributable to Schrödinger common and limited common stockholders, basic: $ (0.67) $ (0.49) $ (1.15) $ (0.49)
Weighted average shares used to compute net loss per share attributable to Schrödinger common and limited common stockholders, basic: 71,161,892 70,582,062 71,106,470 70,328,254
Net loss per share attributable to Schrödinger common and limited common stockholders, diluted: $ (0.67) $ (0.49) $ (1.15) $ (0.49)
Weighted average shares used to compute net loss per share attributable to Schrödinger common and limited common stockholders, diluted: 71,161,892 70,582,062 71,106,470 70,328,254
Software Products and Services        
Revenues:        
Total revenues $ 30,011 $ 24,052 $ 63,092 $ 50,392
Cost of revenues:        
Total cost of revenues 7,101 5,641 14,612 11,547
Drug Discovery        
Revenues:        
Total revenues 8,458 5,732 24,040 11,519
Cost of revenues:        
Total cost of revenues $ 14,234 $ 12,163 $ 27,403 $ 22,220